Market Spotlight: Esophageal Cancer
Market Spotlight: Esophageal Cancer
$1,318.00
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the esophageal cancer market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways:
- Datamonitor Healthcare estimates that in 2019, there were 578,600 incident cases of esophageal cancer worldwide, and expects that number to increase to 618,900 incident cases by 2028.
- Incidence is higher in males compared to females, and is highest in the Asia region. Merck & Co’s Keytruda, Pinnacle Biologics’ Photofrin, Bristol Myers Squibb’s Opdivo, and Jiangsu Hengrui’s camrelizumab are the only marketed drugs for esophageal cancer. These drugs are administered via the intravenous route.
- The largest proportion of industry-sponsored drugs in active clinical development for esophageal cancer are in Phase II. Therapies in development for esophageal cancer focus on a wide variety of targets. The majority of pipeline drugs are administered intravenously, with the remainder being oral and intratumoral formulations.
- High-impact upcoming events for drugs in the esophageal cancer space comprise topline Phase III trial results for Opdivo and Imfinzi, topline Phase II trial results for ADP-A2M4CD8, and expected PDUFA dates for Keytruda and Opdivo.
- The overall likelihood of approval of a Phase I solid tumors asset is 5.3%, and the average probability a drug advances from Phase III is 42.7%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for esophageal cancer have been in the early and mid-phases of development, with 91% of trials in Phase I–II, and only 9% in Phase III–IV.
- The US has a substantial lead in the number of esophageal cancer clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
- Clinical trial activity in the esophageal cancer space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for esophageal cancer, with 93 trials.
- Bristol Myers Squibb leads industry sponsors with the highest overall number of clinical trials for esophageal cancer, closely followed by Roche
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Surgery
9 Radiation therapy
9 Endoscopic therapy
10 Chemotherapy
10 Targeted therapy
10 Immunotherapy
12 EPIDEMIOLOGY
15 MARKETED DRUGS
17 PIPELINE DRUGS
22 RECENT EVENTS AND ANALYST OPINION
22 Tislelizumab for Esophageal Cancer (January 27, 2021)
23 Keytruda for Esophageal Cancer (September 21, 2020)
25 Opdivo for Esophageal Cancer (September 21, 2020)
27 Opdivo for Esophageal Cancer (September 21, 2020)
29 Keytruda for Esophageal Cancer (August 19, 2020)
31 Opdivo for Esophageal Cancer (August 11, 2020)
33 Opdivo for Esophageal Cancer (August 11, 2020)
34 Yervoy for Esophageal Cancer (August 11, 2020)
36 Opdivo for Esophageal Cancer (September 30, 2019)
39 KEY UPCOMING EVENTS
40 KEY REGULATORY EVENTS
40 Opdivo Seeks New Gastric Cancer Uses
40 New Submission For Keytruda In Esophageal Cancer
40 Opdivo First In Gastroesophageal Cancer
40 New China Indications For Merck, Novo, Boehringer Drugs
41 New Indications For Hengrui’s PD-1
41 Supplemental Approvals Boost Opdivo And Gardasil 9, But Limit Beovu
41 UK Early Access Win For New Opdivo Indication
42 EU & US At Odds Over Merck’s Keytruda
43 PROBABILITY OF SUCCESS
44 LICENSING AND ASSET ACQUISITION DEALS
44 Amcure Partners Esophageal Cancer Drug In China With Hinova
44 Pfizer Bets $480m On CStone And Surging China Immuno-Oncology Market
44 AbbVie and China’s Jacobio Pharmaceuticals Unveil Collaboration
45 REVENUE OPPORTUNITY
46 CLINICAL TRIAL LANDSCAPE
47 Sponsors by status
48 Sponsors by phase
49 Recent events
51 BIBLIOGRAPHY
51 Prescription information
53 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of esophageal cancer, 2019–28
14 Figure 2: Incident cases of esophageal cancer, by gender, 2019
17 Figure 3: Overview of pipeline drugs for esophageal cancer in the US
17 Figure 4: Pipeline drugs for esophageal cancer, by company
18 Figure 5: Pipeline drugs for esophageal cancer, by drug type
18 Figure 6: Pipeline drugs for esophageal cancer, by classification
23 Figure 7: Tislelizumab for Esophageal Cancer (January 27, 2021): Phase III – RATIONALE 302
25 Figure 8: Keytruda for Esophageal Cancer (September 21, 2020): Phase III – KEYNOTE-590
27 Figure 9: Opdivo for Esophageal Cancer (September 21, 2020): Phase III – CheckMate-649
29 Figure 10: Opdivo for Esophageal Cancer (September 21, 2020): Phase III – CheckMate-577
31 Figure 11: Keytruda for Esophageal Cancer (August 19, 2020): Phase III – KEYNOTE-590
33 Figure 12: Opdivo for Esophageal Cancer (August 11, 2020): Phase III – CheckMate-577
34 Figure 13: Opdivo for Esophageal Cancer (August 11, 2020): Phase III – CheckMate-649
36 Figure 14: Yervoy for Esophageal Cancer (August 11, 2020): Phase III – CheckMate – 649 (w/Nivolumab)
38 Figure 15: Opdivo for Esophageal Cancer (September 30, 2019): Phase III – ATTRACTION-3
39 Figure 16: Key upcoming events in esophageal cancer
43 Figure 17: Probability of success in the solid tumors pipeline
46 Figure 18: Clinical trials in esophageal cancer
46 Figure 19: Top 10 drugs for clinical trials in esophageal cancer
47 Figure 20: Top 10 companies for clinical trials in esophageal cancer
47 Figure 21: Trial locations in esophageal cancer
48 Figure 22: Esophageal cancer trials status
49 Figure 23: Esophageal cancer trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of esophageal cancer, 2019–28
16 Table 2: Marketed drugs for esophageal cancer
19 Table 3: Pipeline drugs for esophageal cancer in the US
22 Table 4: Tislelizumab for Esophageal Cancer (January 27, 2021)
24 Table 5: Keytruda for Esophageal Cancer (September 21, 2020)
26 Table 6: Opdivo for Esophageal Cancer (September 21, 2020)
28 Table 7: Opdivo for Esophageal Cancer (September 21, 2020)
29 Table 8: Keytruda for Esophageal Cancer (August 19, 2020)
32 Table 9: Opdivo for Esophageal Cancer (August 11, 2020)
33 Table 10: Opdivo for Esophageal Cancer (August 11, 2020)
35 Table 11: Yervoy for Esophageal Cancer (August 11, 2020)
37 Table 12: Opdivo for Esophageal Cancer (September 30, 2019)
45 Table 13: Historical global sales, by drug ($m), 2015–19
45 Table 14: Forecasted global sales, by drug ($m), 2021–25
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Celiac Disease 
Sign up to the